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Abstract
Background: Transanal total mesorectal excision (taTME) is an emerging surgical technique for rectal cancer.
However, the oncological and perioperative outcomes are controversial when compared with conventional
laparoscopic total mesorectal excision (laTME).
Methods: A systematic review and meta-analysis based on Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines was conducted in PubMed, Embase and Cochrane database. All original studies
published in English that compared taTME with laTME were included for critical appraisal and meta-analysis. Data
synthesis and statistical analysis were carried out using RevMan 5.3 software.
Results: A total of seven studies including 573 patients (taTME group = 270; laTME group = 303) were included in
our meta-analysis. Concerning the oncological outcomes, no differences were observed in harvested lymph nodes,
distal resection margin (DRM) and positive DRM between the two groups. However, the taTME group showed a
higher rate of achievement of complete grading of mesorectal quality (OR = 1.75, 95% CI = 1.02–3.01, P = 0.04), a
longer circumferential resection margin (CRM) and less involvement of positive CRM (CRM: WMD = 0.96, 95% CI = 0.
60–1.31, P <0.01; positive CRM: OR = 0.39, 95% CI = 0.17–0.86, P = 0.02). Concerning the perioperative outcomes, the
results for hospital stay, intraoperative complications and readmission were comparable between the two groups.
However, the taTME group showed shorter operation times (WMD = –23.45, 95% CI = –37.43 to –9.46, P <0.01), a
lower rate of conversion (OR = 0.29, 95% CI = 0.11–0.81, P = 0.02) and a higher rate of mobilization of the splenic
flexure (OR = 2.34, 95% CI = 0.99–5.54, P = 0.05). Although the incidence of anastomotic leakage, ileus and urinary
morbidity showed no difference between the groups, a significantly lower rate of overall postoperative
complications (OR = 0.65, 95% CI = 0.45–0.95, P = 0.03) was observed in the taTME group.
Conclusions: In comparison with laTME, taTME seems to achieve comparable technical success with acceptable
oncologic and perioperative outcomes. However, multicenter randomized controlled trials are required to further
evaluate the efficacy and safety of taTME.
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Background
Rectal cancer ranks as one of the most common types of
carcinoma throughout the world [1]. Over recent de-
cades, total mesorectal excision (TME) performed by an
open approach has become the standard technique for
the surgical treatment of rectal cancer [2]. Over time, to
achieve a minimally invasive surgical treatment, TME
has shifted from the open approach to a laparoscopic
technique. Recently published randomized clinical trials
(RCTs), such as COLOR II, COREAN and CLASICC,
have shown better results for laparoscopic total mesorectal
excision (laTME), in terms of short-term and long-term
outcomes, when compared with open TME [3–6]. How-
ever, the utility of laTME is limited in patients with low
rectal cancer, who require surgeons with experience in
ultra-low sphincter-saving laparoscopic surgery, which has
a high risk of leaving a positive circumferential resection
margin (CRM). In addition, narrow pelvic anatomy, male
sex and high body mass index (BMI) are also unfavorable
patient characteristics for a laparoscopic approach [7].
Furthermore, because of the limited view of the distal
margin of the tumor, conversion rates to open procedures
remain unsatisfactory [8, 9]. The pressing need to over-
come these challenges has motivated surgeons to develop
alternative techniques for treatment of rectal cancer,
especially for patients with mid- and low-rectal lesions.
Based on the aforementioned considerations, the con-
cept of a “down-to-up” procedure and transanal TME
(taTME) has been proposed to give a new option in
cases where laTME is difficult. In fact, taTME is not a
completely novel concept and it has benefited from pre-
vious experience of transabdominal–transanal (TATA)
operations, transanal endoscopic microsurgery (TEM),
transanal minimally invasive surgery (TAMIS) and na-
tural orifice transluminal endoscopic surgery (NOTES)
[10–12]. Since the first taTME resection assisted by lapa-
roscopy was reported in 2010 [13], taTME performed on
patients with rectal cancer has showed promising results
with regard to pathological quality, and short- and mid-
term outcomes [14–16]. Although taTME may improve
the distal mesorectal dissection, which is the most tech-
nically challenging part of a transabdominal TME, whether
the oncological and perioperative outcomes of taTME are
better than those of laTME remains controversial. Hence,
a quantitative analysis was necessary to provide direct
evidence of the benefits of taTME.
Therefore, this meta-analysis was conducted to compare
the oncological and perioperative outcomes of taTME and
laTME for patients with mid- and low-rectal cancer.
Methods
Search strategy
This systematic review and meta-analysis were con-
ducted in accordance with Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) guide-
lines (http://www.prisma-statement.org/) [17]. A com-
prehensive search of published studies was performed in
PubMed, Embase and the Cochrane Database (from
January 2010 to November 2015). The MeSH and main
keywords were as follows: “transanal”, “transanal total
mesorectal excision” or “taTME”, “transanal minimally
invasive surgery” or “TAMIS”, “transanal endoscopic
microsurgery” or “TEM”, “natural orifice transluminal
endoscopic surgery” or “NOTES”, “perineal approach”,
“rectal cancer” and “proctectomy”. Based on these MesH
and main keywords, we formulated the search strategy
(for PubMed) as following: (transanal OR transanal
minimally invasive surgery OR TAMIS OR transanal
endoscopic microsurgery OR TEM OR transanal spe-
cimen extraction OR natural orifice specimen extraction
OR NOSE OR natural orifice transluminal endoscopic
surgery OR NOTES OR peritoneal) AND (total meso-
rectal excision OR TME OR proctectomy) AND rectal.
All the relevant studies which described a comparison
between taTME and laTME were checked carefully
(including the reference lists of relevant studies). All
studies were restricted to the English language.
Inclusion and exclusion criteria
According to the PICOS criteria (population, interven-
tion, comparison, outcomes and study design), studies
were selected in our present meta-analysis according to
the following eligibility criteria: (1) population: patients
were definitely diagnosed with rectal cancer; (2) inter-
vention: surgical treatment for rectal cancer (taTME/
laTME); (3) comparison: taTME versus laTME; (4) out-
comes: oncological and perioperative outcomes com-
pared between two groups; (5) study design: randomized
controlled trials, cohort trials or matched case–control
trials with sample size greater than 20. The exclusion
criteria were: (1) no laTME group as a control; (2)
absence of the outcomes of interest; (3) duplicate publi-
cation or provision of insufficient data. All the studies
included were checked carefully once again to avoid the
inclusion of studies which were based on the same data-
base or patient population as another included report.
Data extraction and assessment of the risk of bias
Two reviewers (B Ma and P Gao) reviewed and assessed
each of the included studies. In addition, data extraction
was performed independently, and the following informa-
tion was collected: (1) study characteristics: first author,
year of publication, country, study type (RCT/cohort trial/
matched case–control trial) and number of patients en-
rolled; (2) patient baseline: sex, age, tumor site (mid/low),
tumor location (distance above the anal verge), body mass
index, neoadjuvant treatment, American Society of Anes-
thesiologists (ASA), pT stage and pN stage; (3) study
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design: surgical type of taTME (partial/total), oncological
outcomes (quality of mesorectum, harvested lymph nodes,
CRM, positive CRM, distal resection margin (DRM), posi-
tive DRM and perioperative outcomes (operation time,
conversion, mobilization of splenic flexure, hospital stay,
intraoperative complications, postoperative complications
and readmission). The Newcastle–Ottawa Scale (NOS)
criterion was used to evaluate the quality of the studies
included [18]. All disagreements were resolved by discus-
sion between the two reviewers (B Ma and P Gao).
Statistical analysis
In this meta-analysis, continuous variables representing
the oncological and perioperative outcomes were ana-
lyzed by the weighted mean difference (WMD). If the
study did not provide values for the mean and standard
deviation (SD), we used the method of Hozo et al. to
calculate the mean and SD for our overall analysis [19].
We used odds ratios (ORs) to evaluate the dichotomous
variables for the oncological and perioperative outcomes.
In addition, the Q test and I2 statistic were used to eva-
luate heterogeneity among studies. A Cochrane Q statis-
tical P value <0.10 and/or I2 > 50% was taken to indicate
significant heterogeneity, and in this case a random-
effects model was used for the pooled analysis [20, 21].
Otherwise, a fixed-effects model was employed. All statis-
tical values were computed with 95% confidence intervals
(CI), and the two-tailed P value threshold for statistical
significance was set at 0.05. Furthermore, based on the
surgical type of taTME, we conducted a subgroup analysis
to explore further the advantages of total taTME using a
laparoscopic approach. Finally, publication bias was tested
using funnel plots. All the statistical analyses were per-
formed using software from the Cochrane Collaboration
(RevMan v5.3; Nordic Cochrane Centre).
Results
Selected studies
The search strategy initially identified 923 studies (Pubmed
= 275; other databases = 648). After exclusion of duplicates
and irrelevant studies, 11 potentially relevant studies were
obtained for further assessment. Among these studies, three
studies were conference abstracts from which we could not
extract sufficient information for our final analysis [22–24].
In addition, one report described a protocol for a multi-
center RCT comparing transanal TME and laTME for mid-
and low-rectal cancer [25]. Finally, seven studies including
573 patients were included our meta-analysis (taTME
group = 270; laTME group = 303) [26–32]. A flow chart of
the search strategies, which includes the reasons for exclu-
sion of studies, is illustrated in Fig. 1. The seven studies
were from France, the Netherlands, Taiwan, Spain and
Denmark. The study characteristics, patient baseline data
and methodological quality assessment scores of the studies
included are summarized in Table 1.
Oncological outcomes
The quality of the mesorectum was scored using three
grades (complete, nearly complete and incomplete), as
defined by Quirke [33]. On the basis of this standardized
method, five of the studies included reported the macro-
scopic quality of the mesorectum [26, 28, 29, 31, 32].
After pooled analysis, the complete grade for the quality
of the mesorectum was significantly higher for taTME
than for laTME (OR = 1.75, 95% CI = 1.02–3.01, P = 0.04;
Fig. 2a). All the studies included provided information
on harvested lymph nodes. The pooled analysis of the
seven studies showed that harvested lymph nodes were
equivalent between the two groups (WMD= 0.00, 95%
CI = –1.24–1.25, P = 1.00; Fig. 2b).
With regard to the surgical resection margin, all the
studies provided sufficient data on CRM and DRM.
Among them, three studies reported patients who
achieved complete remission after neoadjuvant treatment
[28–30] and two studies evaluated the CRM and DRM
only in patients without complete response after neoadju-
vant treatment [29, 30]. We excluded the patients with
complete remission in these two studies from our overall
analysis of the outcomes of CRM and DRM. In the pooled
data, the taTME group showed a significantly greater
CRM than the laTME group (WMD= 0.96, 95% CI =
0.60–1.31, P <0.01; Fig. 2c), but a comparable DRM was
observed between the two groups (WMD = 2.71, 95%
CI = –1.97–7.39, P = 0.26; Fig. 2d). Among the studies,
six provided data on positive CRM [26–29, 31, 32]
and three on positive DRM [27, 29, 32]. Meta-analysis
indicated that a significantly lower number of patients
in the taTME group had a positive CRM (OR = 0.39,
95% CI = 0.17–0.86, P = 0.02; Fig. 2e), but there was
comparable DRM involvement between the two groups
(OR = 1.65, 95% CI = 0.17–16.40, P = 0.67; Fig. 2f).
Except for the outcomes of DRM and positive DRM,
all the other oncological outcomes showed no significant
heterogeneity between the groups. Detailed information
on the oncological outcomes of included studies is sum-
marized in Table 2.
Perioperative outcomes
Given that Velthuis et al. [31] only provided results on
the pathological characteristics, a meta-analysis was
conducted using the remaining six studies to compare
the operative and perioperative outcomes between the
two groups. In terms of operative outcomes, data on
operation time, conversion rate and hospital stay were
available for these six studies [26–30, 32]. After pooled
analysis, we found that the taTME group showed a
significantly shorter operation time (WMD = –23.45,
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95% CI = –37.43 to –9.46, P <0.01; Fig. 3a), a lower
conversion rate (OR = 0.29, 95% CI = 0.11–0.81, P = 0.02;
Fig. 3b) and a comparable hospital stay (WMD = –1.18,
95% CI = –2.94–0.59, P = 0.19; Fig. 3c). Three studies
provided data on mobilization of the splenic flexure in
the two groups [26, 28, 30] and more mobilization of the
splenic flexure was achieved in the taTME group (OR =
2.34, 95% CI = 0.99–5.54, P = 0.05; Fig. 3d). In addition, a
pooled analysis of intraoperative complications, based
on four studies, was conducted [26, 28–30] and there
was no difference between the groups for this outcome
(OR = 0.94, 95% CI = 0.30–3.01, P = 0.92; Fig. 3e). Two
studies also indicated that the taTME group showed
significantly less blood loss [26, 30] and we did not
conduct a pooled analysis because the low number of
studies caused considerable heterogeneity.
Regarding the short-term outcomes, all six remaining
studies provided information about postoperative com-
plications. In the pooled data, the taTME group showed
a significantly lower rate of postoperative complications
than the laTME group (OR = 0.65, 95% CI = 0.45–0.95,
P = 0.03; Fig. 4a). Of note, the occurrence of anastomotic
leakage, ileus and urinary morbidity was comparable
between the two groups (anastomotic leakage: OR =
0.78, 95% CI = 0.44–1.40, P = 0.41; ileus: OR = 1.00, 95%
CI = 0.45–2.19, P = 1.00; urinary morbidity: OR = 0.48,
95% CI = 0.22–1.03, P = 0.06; Fig. 4b–d). In addition,
four studies reported the readmission rate [26, 28–30].
A pooled analysis showed a tendency that fewer patients
after taTME would require readmission, although this
was not statistically significant (OR = 0.52, 95% CI =
0.24–1.10, P = 0.09; Fig. 4e).
Except for operative time, hospital stay and molization of
splenic flexure, no significant heterogeneity was observed
between the groups for other perioperative outcomes.
Detailed information on the perioperative outcomes of
included stuedies is also summarized in Table 2.
Subgroup analyses
The term taTME includes two different concepts (partial
and total taTME) [34]. Among the studies included in
the meta-analysis, two reported the use of conventional
retractors to perform a partial taTME [27, 32] the other
five studies used a standard transanal access platform to
perform a total taTME [26, 28–31]. Hence, to eliminate
the heterogeneity introduced by differences in surgical
technique, we conducted a subgroup analysis of the
oncological and perioperative outcomes, based on total
taTME, to further verify our pooled results. Our sub-
group analysis showed that the benefits of total taTME
were obvious, which was consistent with our overall ana-
lysis (Table 3).
Discussion
Laparoscopic procedures are generally thought to have
better outcomes than open procedures. However, recent
two RCTs (AlaCaRT and ACOSOG Z6051) both confirmed
that laparoscopic resection failed to meet the criterion for
noninferiority for pathologic outcomes when compared
with open section for rectal cancer patients [35, 36]. An
Fig. 1 Flow chart showing the selection process for the included studies
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Table 1 Baseline characteristics of the included studies
Studies
(NOS score)
Year Country Study design Gender
Male/Female
BMI Mean ± SD/median
(range)
Age Mean ± SD/median
(range)
ASA I + II/III + IV Tumor location Neoadjuvant treatment
(Yes/No)
taTME type
taTME laTME taTME laTME taTME laTME taTME laTME taTME laTME
Velthuis [31]
(3) 2014
Netherland MCC 18/7 18/7 25 (20-36) 28 (21-34) NR NR NR NR low/mid 25/0 25/0 Total
Kanso [27] (6) 2015 France MCC 36/15 26/8 24 ± 4 24 ± 4 59 ± 11 59 ± 11 47/4 31/3 low 43/41a 28/27a Partial
Hevia [28] (4) 2014 Spain MCC 24/13 22/15 23.7 ± 3.6 25.1 ± 4.0 64.5 ± 11.8 69.5 ± 10.5 30/7 25/12 low/mid 28/9 23/14 Total
Chen [30] (4) 2015 Taiwan MCC 38/12 76/24 24.2 ± 3.7 24.6 ± 3.1 57.3 ± 11.9 58.3 ± 11.3 33/17 69/31 low/mid 50/0 100/0 Total
Denost [32]
(6) 2014
France RCT 37/13 32/18 25 (17-33) 26 (18-38) 64 (39-82) 63 (31-90) 49/1 49/1 low 40/10 44/6 Partial
Perdawood
[26] (4) 2015
Denmark MCC 19/6 19/6 28 (18-46) 26 (19-38) 70 (54-76) 70 (49-84) 19/6 22/3 low/mid 7/18 4/21 Total
Angelis [29]
(4) 2015
France MCC 21/11 21/11 25.2 ± 3.5 24.5 ± 3.2 64.9 ± 10.0 67.2 ± 9.6 31/1 31/1 low/mid 27/5 23/9 Total
taTME transanal total mesorectal excision, laTME laparoscopic total mesorectal excision, BMI body mass index, ASA American Society of Anesthesiologists, MCC matched case control, RCT randomized controlled trial,













explanation for this finding is that proctectomy can be very
difficult to work in the deep pelvis with in-line rigid instru-
ments from angles that require complicated maneuvers to
reach the extremes of the pelvis. Hence, both AlaCaRT and
ACOSOG Z6501 indicated that modification of instru-
ments or a different platform such as robotics or taTME
will improve efficacy of minimally invasive techniques. Over
the last decade, transanal approaches have been extensively
used to overcome the inherent shortcomings of laTME
[37–39]. Among these emerging transanal techniques,
taTME is a new minimally invasive procedure with essen-
tial aim of improving oncological treatment quality and
avoiding pelvic nerve injury in patients with mid- or low-
rectal cancer. Given the encouraging outcomes of syste-
matic investigation of taTME for patients with rectal
cancer [40, 41] taTME may be optimized as a surgical
Fig. 2 Forest plot based on oncological outcomes (a) Mactosocopic quality of mesoretum (b) Harvested lymph nodes (c) Circumferential
resection margin (d) Distal resection margin (e) Positive circumferential resection margin (f) Positive distal resection margin
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approach for rectal cancer. In comparison with conven-
tional laTME, taTME defines the distal resection margin
more precisely, with better visualization of the distal
rectum, and allows the surgeon to perform the deep pelvic
dissection without the need for difficult retraction (even
in the deep, narrow male pelvis or in obese patients) [42].
Heald has already stressed the importance of taTME as a
new solution to some old problems [43]. However, the
benefits of taTME compared with laTME must be con-
firmed before carrying out multicenter RCTs and unifying
taTME procedures. Hence, we conducted this quantitative
meta-analysis to investigate whether taTME can show
significant benefits with regard to oncological and peri-
operative outcomes, when compared with laTME.
Based on the results of our meta-analysis for onco-
logical outcomes, we found that patients in the taTME
group had a significantly higher rate of complete speci-
mens, longer CRM and less positive CRM involvement.
In addition, in terms of perioperative outcomes, the
taTME group had significantly shorter operation times
and a lower conversion rate. Of note, a significantly lower
rate of postoperative complications was observed in the
taTME group in comparison with the laTME group. Our
findings have provided direct evidence that taTME shows
benefits with regard to short-term outcomes for patients
with rectal cancer.
Our overall and subgroup analyses both indicated the
significant advantages of taTME in achieving complete
grading of mesorectal quality. Complete or nearly complete
mesorectal fascia is a recognized and universally accepted
positive prognostic factor, whereas an incomplete fascia is
associated with unfavorable oncological outcomes [44].
Based on the studies included, the percentage of patients
with complete mesorectum was 83.4% in the taTME group
and 73.4% in the laTME group. In addition, achievement of
complete plus nearly complete mesorectum was also
greater in the taTME group (95.3% versus 88.2%). Hence,
for patients with mid- or low-rectal cancer, taTME may
achieve a complete or nearly complete resection of the
mesorectum relative easily, compared with laTME. How-
ever, whether a higher quality of mesorectal resection will
convert into longer survival remains unknown.
Table 2 Detailed information of oncological and perioperative outcomes of included studies
Studies Velthuis [31] Kanso [27] Hevia [28] Chen [30] Denost [32] Perdawood [26] Angelis [29]
Mactoscopic quality of mesorectum * * * * *
Harvested lymph nodes * * * * * * *
Circumferential resection margin * * * * * * *
Positive circumferential resection margin * * * * * *
Distal resection margin * * * * * * *
Positive distal resection margin * * *
Length of resected specimen * *
Complete remission after neoadjuvant * * *
Operative time * * * * * *
Conversion * * * * * *
Hospital stay * * * * * *
Intraoperative complications * * * *
Postoperative complications * * * * * *
Anastomotic leakage * * * * * *
Ileus * * * * *
Acute urinary retention * * * * *
Blood loss * *
Mobilization of splenic flexure * * *
Readmission * * * *
Mortality * * *
Type of anastomosis * * * *
Disease-free survival *
Starting diet period *
Days to Foley removal *
Diverting Ostomy * *
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The CRM and positive CRM are important indicators
of the outcome for patients undergoing TME for rectal
cancer [45, 46]. Our results confirmed a significant
advantage of taTME in CRM and less positive CRM
involvement. However, for the DRM and positive DRM,
our results did not reach statistical significance. On one
hand, considerable heterogeneity was observed for these
two outcomes, which may have been caused by diffe-
rences in tumor location. In fact, two studies enrolled
patients with only low rectal cancer [27, 32], the other
five studies enrolled patients with mid- or low-rectal
cancer [26, 28–31]. On the other hand, a significant
difference in the distance of the tumor from the anal
verge was observed in Chen’s study (P = 0.022) [30].
Although we could not eliminate the heterogeneity of
DRM and positive DRM in our present study, on the
basis of the rationale of the dissection in taTME, the
potential advantages in these two outcomes justify further
study in a large RCT.
With regard to the operative outcomes, taTME and
laTME showed comparable results for hospital stay and
readmission rate. However, a significantly shorter ope-
ration time and lower conversion rate were observed for
taTME. One explanation is that taTME can be performed
by two teams simultaneously, which obviously decreased
the operation time in the pooled analysis [28, 30]. How-
ever, it is noteworthy that six of the included studies
showed a shorter operation time for the taTME group,
irrespective of whether one or two teams were working.
The “down-to-up” procedure indeed overcomes the
technical limitations of laparoscopy and helps surgeons
perform the surgical procedures efficiently. In addition,
we assessed the reasons for conversion of the approach. In
the taTME group, only one patient underwent conversion
Fig. 3 Forest plot based on perioperative outcomes (a) Operative time (b) Conversion (c) Hospital stay (d) Mobilization of splenic flexure
(e) Intraoperative complications
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Fig. 4 Forest plot based on perioperative outcomes (a) Postoperative complications (b) Anastomotic leakage (c) Ileus (d) Urinary morbidity
(e) Readmission
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to and open approach because of technical difficulty
(1/4; 25%), whereas eight patients in the laTME group
(8/17; 47%) underwent conversion. The significantly
higher conversion rate in the laTME group was primarily
due to the difficult pelvic approach in patients with
unfavorable characteristics; taTME may overcome these
limitations to decrease the incidence of conversion.
Furthermore, our results showed a higher rate of mobli-
zation of splenic flexure in taTME group. Hence, we want
to explore whether use of diverting ostomy may be an
affecting factor for moblization of splenic flexure in our
present study. Two included studies reported the data of
using ostomy between two groups [28, 30]. In study of
Hevia et al [28], 86% (32/37) patients in taTME group used
diverting ileostomy and 81% (30/37) patients in laTME
group (P = 0.53). In addition, Chen et al [30] indicated that
92% (46/50) patients in taTME group underwent pro-
tective enterostomy in comparison with 91% (91/100)
patients in laTME group (P = 0.839). Based on this limited
data, both groups showed equal rate of using ostomy and
we could not get a definite correlation between under-
going ostomy and easier taking down splenic flexure in
taTME group. Therefore, the potential factors affecting
mobilization of splenic flexure in taTME cases needed to
be further explored.
Safety is always the most important issue for a new
technique. Our meta-analysis indicated a comparable
rate of intraoperative complications and a significantly
lower incidence of postoperative complications in the
taTME group when compared with the laTME group.
The tendency for a lower incidence of postoperative
complications in the taTME group may also explain the
lower readmission rate for these patients in comparison
with the laTME group. However, these results need to
be interpreted with caution because they are derived
mainly from retrospective studies. Among the types of
postoperative complication, our pooled analysis showed
that the incidence of anastomotic leakage, ileus and
urinary morbidity were comparable between the two
groups. In fact, one of the included studies showed a
higher incidence of anastomotic leakage in the taTME
group [28]. The height of the anastomosis, a risk factor
for the development of leakage, may explain this finding
[47]. The distance of the tumor from the dentate line
varied in the studies included, and was lower in the
taTME group (1.6 cm versus 1.8 cm; P = 0.11). Of
note, an obviously lower incidence of urinary morbidity
(infection, dysfunction and retention) was observed in the
taTME group, although this did not reach statistical
significance. A possible explanation is that taTME provides
improved pelvic visualization with enhanced anatomical
definition, allowing more accurate dissection through the
presacral plane between the mesorectal and pelvic fascia,
which may result in sparing of the autonomic nerves during
Table 3 Subgroup analysis based on total taTME
Outcomes No. of patients No. of studies OR/WMD 95%CI Heterogeneity P
valuetaTME laTME Low high I2 P value
Oncological outcomes
Mactoscopic quality of mesorectum 119 119 4 2.03 0.99 4.16 11% 0.34 0.05
Harvested lymph nodes 169 219 5 −0.45 −1.98 1.08 0% 0.93 0.56
Circumferential resection margin 161 205 5 0.94 0.57 1.30 20% 0.29 <0.01*
Positive circumferential resectionmargin 119 119 4 0.31 0.08 1.18 0% 0.90 0.09
Distal resection margin 161 205 5 5.48 −0.17 11.13 73% <0.01 0.06
Positive distal resection margin 83 66 2 5.98 0.71 50.5 0% 0.92 0.10
Perioperative outcomes
Operative time 144 194 4 −23.29 −45.60 -0.98 72% 0.01 0.04*
Conversion 144 194 4 0.31 0.08 1.18 0% 0.90 0.09
Hospital stay 144 194 4 −1.62 −3.62 0.38 74% 0.01 0.11
Intraoperative complications 144 194 4 0.94 0.30 3.01 0% 0.60 0.92
Postoperative complications 144 194 4 0.59 0.35 0.97 45% 0.14 0.04*
Anastomotic leakage 144 194 4 0.65 0.30 1.42 0% 0.66 0.28
Ileus 144 194 4 1.37 0.45 4.13 0% 0.49 0.58
Acute urinary retention 144 194 4 0.45 0.18 1.10 0% 0.81 0.08
Mobilization of splenic flexure 112 162 3 2.34 0.99 5.54 54% 0.12 0.05
Readmission 144 194 4 0.52 0.24 1.10 0% 0.57 0.09
taTME transanal total mesorectal excision, laTME laparoscopic total mesorectal excision, OR odds ratios, WMD weighted mean difference, CI confidence interval;
*P vaule with statistical significance
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mesorectal dissection, and therefore result in a lower
incidence of urinary dysfunction [39, 42]. However, little is
known about the long-term quality of life of these patients,
or about the risk and the incidence of sexual and urinary
dysfunction related to this procedure. Hence, the benefits
of taTME with regard to postoperative complications need
to be verified by multicenter RCTs.
As the new surgical technique of taTME is adopted
increasingly by surgeons, the patient selection criteria
will be crucial and will continue to animate debate. Based
on the studies included in our meta-analysis, taTME was
performed primarily in patients requiring surgical resec-
tion for mid- and low-rectal cancer. In addition, taTME
may be more suitable for male patients with high BMI
and a narrow pelvis. The study of Rouanet et al. [7] also
confirmed that taTME is a feasible alternative surgical
option to conventional laparoscopy for patients with
unfavorable characteristics. Of note, the protocol pub-
lished recently for a multicenter RCT comparing taTME
with laTME (COLOR III) has formulated strict criteria for
patient selection [25]. According to the selection criteria
of this protocol, T3 tumors with margins <1mm to the
endopelvic fascia, tumors with ingrowth in the internal
sphincter or m. levator ani and all T4 tumors as staged
prior to neoadjuvant therapy were excluded [25]. How-
ever, the nature of the surgical candidates best suited to
taTME treatment requires further study.
There were some limitations to our present meta-
analysis. Except for one study (a RCT by Denost et al.)
[32], the other studies included were all retrospective
matched case–control trials, which slightly decreases the
power of our meta-analysis. In addition, the results on
both taTME and laTME were obtained at high volume
centers with large minimally invasive proctectomy expe-
riences. Hence, whether the comparable technical success
of taTME could be achieved in low volume centers
remained further study before this technique fully accepted
by surgeon. Furthermore, a standardized procedure and
transanal access platform of taTME were not formulated,
and differences among the studies in surgical procedure
and instruments may have contributed to the heterogeneity
in our pooled analysis. Meanwhile, our study only indicated
the benefits of taTME in short-term outcomes, compared
with laTME; the long-term oncological and functional
results should be awaited before completely adopting this
new technique. Furthermore, the patients enrolled in our
meta-analysis showed inconsistencies with regard to base-
line information (age, BMI, neoadjuvant treatments, ASA,
pT and pN stage). For example, the patients in the taTME
group of the study by Perdawood et al. [26] showed a
obviously higher BMI when compared with those in the
laTME group (P = 0.07), the patients in the study of Hevia
et al. [28] showed a difference in age between the two
groups (P = 0.06), and the distance of tumor the above the
anal verge showed a significant difference between groups
in Chen’s study (P = 0.02) [30]. Importantly, neoadjuvant
treatments may be a potential confounding factor for the
oncological outcomes of rectal cancer [48]. However, we
could not conduct a subgroup analysis based on whether
patients had received neoadjuvant treatments before sur-
gical resection by all the possible means. Although the
taTME group yielded longer distal margin lengths
compared with laTME in the study of Chen et al. [30]
(in which all the patients received neoadjuvant chemo-
radiation before surgery), studies stratified on the basis
of neoadjuvant treatment are needed to verify the ad-
vantages of taTME.
Conclusion
Although some limitations existed in present study,
our meta-analysis first provides that taTME can
achieve comparable technical success in comparison
with laTME, in the treatment of rectal cancer. Multi-
center RCTs comparing taTME with laTME with long-
term outcomes are required to evaluate the efficacy
and safety of taTME further as a valid treatment for
rectal cancer.
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